| Ytd | -39.29% | |
| 1y | -45.43% |
| Open | 0.91 | Prev Close | 0.92 | Low | 0.91 | High | 0.95 | Mkt Cap | 38.52M |
| Vol | 38.62K | Avg Vol | 109.12K | EPS | -1.45 | P/E | -0.63 | Forward P/E | -2.14 |
| Beta | 1.48 | Short Ratio | 0.47 | Inst. Own | 5.96% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | N/A | 50-d Avg | 0.97 | 200-d Avg | 1.22 | 1yr Est | 12.08 |
Optimized Oral Formulation Demonstrates Favorable Oral Bioavailability Together with Robust Brain an
MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA) ("MIRA" or the "Company"), a clinical-stage
Study Overview and Key FindingsResearchers tested THC and Mira-55, along with rimonabant's abili
U.S. stock futures were slightly higher on Thursday after a mixed close on Wednesday. Futures of maj